JP2014526511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526511A5 JP2014526511A5 JP2014530796A JP2014530796A JP2014526511A5 JP 2014526511 A5 JP2014526511 A5 JP 2014526511A5 JP 2014530796 A JP2014530796 A JP 2014530796A JP 2014530796 A JP2014530796 A JP 2014530796A JP 2014526511 A5 JP2014526511 A5 JP 2014526511A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sodium
- highly polar
- sulfur
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 230000036542 oxidative stress Effects 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000006071 cream Substances 0.000 claims 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 208000024963 hair loss Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 2
- 235000011152 sodium sulphate Nutrition 0.000 claims 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 2
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 229940056585 ammonium laurate Drugs 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- XYXNTHIYBIDHGM-UHFFFAOYSA-N ammonium thiosulfate Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=S XYXNTHIYBIDHGM-UHFFFAOYSA-N 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- VJCJAQSLASCYAW-UHFFFAOYSA-N azane;dodecanoic acid Chemical compound [NH4+].CCCCCCCCCCCC([O-])=O VJCJAQSLASCYAW-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- LVGQIQHJMRUCRM-UHFFFAOYSA-L calcium bisulfite Chemical compound [Ca+2].OS([O-])=O.OS([O-])=O LVGQIQHJMRUCRM-UHFFFAOYSA-L 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 235000010260 calcium hydrogen sulphite Nutrition 0.000 claims 1
- FAYYUXPSKDFLEC-UHFFFAOYSA-L calcium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Ca+2].[O-]S([O-])(=O)=S FAYYUXPSKDFLEC-UHFFFAOYSA-L 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 claims 1
- 229940099427 potassium bisulfite Drugs 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 claims 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims 1
- 229910052939 potassium sulfate Inorganic materials 0.000 claims 1
- 235000011151 potassium sulphates Nutrition 0.000 claims 1
- MQOCIYICOGDBSG-UHFFFAOYSA-M potassium;hexadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCC([O-])=O MQOCIYICOGDBSG-UHFFFAOYSA-M 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 229940045870 sodium palmitate Drugs 0.000 claims 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000004647 tinea pedis Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000011479 upper respiratory tract disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534585P | 2011-09-14 | 2011-09-14 | |
| US61/534,585 | 2011-09-14 | ||
| PCT/US2012/055205 WO2013040240A1 (en) | 2011-09-14 | 2012-09-13 | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014526511A JP2014526511A (ja) | 2014-10-06 |
| JP2014526511A5 true JP2014526511A5 (enExample) | 2015-05-21 |
Family
ID=47830038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530618A Expired - Fee Related JP5992525B2 (ja) | 2011-09-14 | 2012-09-13 | 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 |
| JP2014530796A Pending JP2014526511A (ja) | 2011-09-14 | 2012-09-13 | 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530618A Expired - Fee Related JP5992525B2 (ja) | 2011-09-14 | 2012-09-13 | 高度に生物学的に利用可能なゼロ価硫黄の調製及び組成物並びにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8771755B2 (enExample) |
| EP (2) | EP2756757B1 (enExample) |
| JP (2) | JP5992525B2 (enExample) |
| CN (2) | CN104080334A (enExample) |
| AU (3) | AU2012321444B2 (enExample) |
| BR (3) | BR112014005144B1 (enExample) |
| CA (2) | CA2847589C (enExample) |
| ES (1) | ES2739628T3 (enExample) |
| HK (1) | HK1200278A1 (enExample) |
| MX (3) | MX360050B (enExample) |
| WO (2) | WO2013055199A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
| US9306218B2 (en) | 2011-08-11 | 2016-04-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them |
| US11795248B2 (en) | 2011-08-11 | 2023-10-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur and epoxy functional styrenics |
| US11015023B2 (en) | 2011-08-11 | 2021-05-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Fire retardant compositions utilizing elemental sulfur |
| US10920020B2 (en) | 2011-08-11 | 2021-02-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | 3D-printing of ultra-high refractive index polymers |
| US9567439B1 (en) | 2011-08-11 | 2017-02-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sulfur composites and polymeric materials from elemental sulfur |
| HK1200278A1 (en) * | 2011-09-14 | 2015-08-07 | Nuevas Alternativas Naturales, S.A.P.I. de C.V. | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
| US10894863B2 (en) | 2014-02-14 | 2021-01-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Cathode materials for Li—S batteries |
| KR20160122838A (ko) * | 2014-02-14 | 2016-10-24 | 더 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 | 원소 황에서 유래된 황 복합체 및 폴리머 재료 |
| US9795676B2 (en) | 2014-03-03 | 2017-10-24 | Shayne Kenneth Morris | Chromium 4-hydroxyisoleucinate compound methods for prepartion and use |
| EP3151671A4 (en) * | 2014-06-03 | 2018-03-07 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| JP6806965B2 (ja) * | 2014-07-29 | 2021-01-06 | 国立大学法人 筑波大学 | 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法 |
| WO2016159612A1 (ko) * | 2015-03-27 | 2016-10-06 | 서울대학교산학협력단 | 폴리설파이드 공중합체 나노입자 및 그의 제조 방법 |
| US11078333B2 (en) | 2015-07-13 | 2021-08-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials |
| US10238685B2 (en) * | 2015-12-02 | 2019-03-26 | Johnson & Johnson Consumer Inc. | Compositions containing polymeric sulfur and uses thereof |
| US20170252369A1 (en) * | 2016-03-03 | 2017-09-07 | Frederick J. Sawaya | Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases |
| CN107281215A (zh) * | 2016-04-01 | 2017-10-24 | 复旦大学附属妇产科医院 | 硫化氢供体硫氢化钠在制药中的用途 |
| WO2018107169A1 (en) | 2016-12-09 | 2018-06-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Metallopolymers for catalytic generation of hydrogen |
| JP6989157B2 (ja) * | 2017-02-09 | 2022-01-05 | ノクサノ インコーポレイテッド | 電気化学ガス状伝達物質生成組成物及びその使用方法ならびにそれを組み込んだ被覆材及び治療システム |
| US20180271823A1 (en) * | 2017-03-23 | 2018-09-27 | Washington State University | Sulfur-based broad spectrum antivirals |
| US11674005B2 (en) | 2017-06-15 | 2023-06-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization |
| FR3072024A1 (fr) * | 2017-10-11 | 2019-04-12 | Olivier Petitjean | Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale |
| CN108486081B (zh) * | 2018-05-04 | 2021-07-02 | 山西大学 | 一种植物巯基丙酮酸硫转移酶及其应用 |
| WO2020046635A1 (en) * | 2018-08-28 | 2020-03-05 | The Regents Of The University Of California | Tetrathionate for cyanide and methylmercaptan poisoning |
| WO2021092392A1 (en) * | 2019-11-07 | 2021-05-14 | Cornell University | Use of membrane inhibitors to enhance vaccine development against enveloped viruses |
| WO2021226037A1 (en) * | 2020-05-04 | 2021-11-11 | Sulfagenix, Inc. | Treatment of viral infections |
| FR3125409A1 (fr) * | 2021-07-26 | 2023-01-27 | Nuribiol | Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine |
| IT202100021548A1 (it) * | 2021-08-09 | 2023-02-09 | Universita’ Di Pisa | Coniugati della metformina e loro impiego terapeutico |
| WO2023079466A2 (en) * | 2021-11-03 | 2023-05-11 | Sulfagenix, Inc. | Treatment of sequelae of coronavirus infections |
| EP4212149A1 (en) | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
| WO2024127426A1 (en) * | 2022-12-12 | 2024-06-20 | Polishetty Ravishankar | An herbal formulation prs-01 for regeneration of the cardiomyocytes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1213050B (it) * | 1986-03-14 | 1989-12-07 | Schiena Ricerche | Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare |
| US5100653A (en) * | 1991-02-08 | 1992-03-31 | Giovanni Campo | Topical compositions for treating mouth tissues |
| US6855342B2 (en) * | 2000-06-30 | 2005-02-15 | Medicis Pharmaceutical Corporation | Compositions and methods for high sorption of skin materials and delivery of sulfur |
| US6514489B1 (en) * | 2000-06-30 | 2003-02-04 | Medicis Pharmaceutical Corp. | Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| AUPS255402A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with oxidative stress |
| US8361514B2 (en) * | 2002-06-19 | 2013-01-29 | Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| US20030235571A1 (en) | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
| CN1320925C (zh) * | 2005-03-30 | 2007-06-13 | 淮北市辉克药业有限公司 | 长期使用的治疗糖尿病的复方制剂 |
| US7741359B2 (en) | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| US20100172992A1 (en) * | 2006-06-02 | 2010-07-08 | Natural Ma Inc. | Pathogenic attenuation via the administration of an equilibiotic compound |
| US7923037B2 (en) | 2006-10-05 | 2011-04-12 | Ikaria, Inc. | Liquid chalcogenide compositions and methods of manufacturing and using the same |
| US20120135091A1 (en) * | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| EP2170356A1 (en) * | 2007-06-25 | 2010-04-07 | Fred Hutchinson Cancer Research Center | Methods and compositions regarding polychalcogenide compositions |
| EP2167068A2 (en) | 2007-07-05 | 2010-03-31 | Inserm-Institut National De La Sante Et De La Recherche Medicale | Anticonvulsive pharmaceutical compositions |
| CN101467991B (zh) * | 2007-08-02 | 2012-02-01 | 复旦大学 | 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途 |
| US20110172171A1 (en) | 2008-09-12 | 2011-07-14 | Serge Picaud | Taurine or taurine-like substances for the prevention of brain oedema |
| RU2406477C1 (ru) | 2009-08-25 | 2010-12-20 | Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") | Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов |
| US8680151B2 (en) * | 2010-02-11 | 2014-03-25 | Fred Hutchinson Cancer Research Center | Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury |
| WO2012075242A2 (en) | 2010-12-01 | 2012-06-07 | Washington State University Research Foundation | Controlled chemical release of hydrogen sulfide |
| HK1200278A1 (en) * | 2011-09-14 | 2015-08-07 | Nuevas Alternativas Naturales, S.A.P.I. de C.V. | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
-
2012
- 2012-09-13 HK HK15100737.1A patent/HK1200278A1/xx unknown
- 2012-09-13 EP EP12840653.5A patent/EP2756757B1/en active Active
- 2012-09-13 WO PCT/MX2012/000086 patent/WO2013055199A1/es not_active Ceased
- 2012-09-13 WO PCT/US2012/055205 patent/WO2013040240A1/en not_active Ceased
- 2012-09-13 US US13/614,820 patent/US8771755B2/en active Active
- 2012-09-13 BR BR112014005144-5A patent/BR112014005144B1/pt not_active IP Right Cessation
- 2012-09-13 BR BR112014004859A patent/BR112014004859A2/pt unknown
- 2012-09-13 JP JP2014530618A patent/JP5992525B2/ja not_active Expired - Fee Related
- 2012-09-13 MX MX2014003289A patent/MX360050B/es active IP Right Grant
- 2012-09-13 ES ES12840653T patent/ES2739628T3/es active Active
- 2012-09-13 MX MX2018012760A patent/MX386642B/es unknown
- 2012-09-13 BR BR122020020392-7A patent/BR122020020392B1/pt not_active IP Right Cessation
- 2012-09-13 CA CA2847589A patent/CA2847589C/en active Active
- 2012-09-13 CN CN201280055604.5A patent/CN104080334A/zh active Pending
- 2012-09-13 AU AU2012321444A patent/AU2012321444B2/en not_active Ceased
- 2012-09-13 US US14/345,044 patent/US20150064286A1/en not_active Abandoned
- 2012-09-13 MX MX2014003288A patent/MX2014003288A/es unknown
- 2012-09-13 CA CA2847264A patent/CA2847264A1/en not_active Abandoned
- 2012-09-13 EP EP12830924.2A patent/EP2755478A4/en not_active Withdrawn
- 2012-09-13 JP JP2014530796A patent/JP2014526511A/ja active Pending
- 2012-09-13 AU AU2012308501A patent/AU2012308501A1/en not_active Abandoned
- 2012-09-13 CN CN201280055643.5A patent/CN104080339B/zh not_active Expired - Fee Related
-
2014
- 2014-04-16 US US14/254,396 patent/US20140322361A1/en not_active Abandoned
-
2015
- 2015-08-06 AU AU2015210403A patent/AU2015210403B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526511A5 (enExample) | ||
| CN103167877A (zh) | 包含谷胱甘肽还原酶和氧化型谷胱甘肽的组合物，以及其治疗用途 | |
| NO20045557L (no) | Kombinasjon av en DPP IV inhibitor og en kardiovaskulaer forbindelse | |
| HRP20250931T1 (hr) | Pripravak za upotrebu u postupku liječenja prekomjerne težine i pretilosti kod pacijenata s visokim kardiovaskularnim rizikom | |
| JP2022501331A (ja) | 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法 | |
| Lin et al. | Early postoperative complications in recipients of living donor liver transplantation | |
| EA201070084A1 (ru) | Новое применение известных фармакологически активных химических соединений | |
| CN101461525A (zh) | 预防心脑血管疾病专用面粉 | |
| Ibrahim et al. | Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis | |
| JP2014504628A5 (enExample) | ||
| Sethi et al. | Diluted Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Pediatric Patients: Suggested Practice Points | |
| Souza et al. | L-Arginine supplementation blunts resistance exercise improvement in rats with chronic kidney disease | |
| Auerbach et al. | The iron revolution: Keeping abreast of the developments in iron therapy | |
| Susic et al. | Telmisartan improves survival and ventricular function in SHR rats with extensive cardiovascular damage induced by dietary salt excess | |
| KR20220015428A (ko) | 단백질 클로토(Klotho)의 생산을 활성화할 수 있는 시트레이트 및 카르니틴을 포함하는 조성물 | |
| Watorek et al. | Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors | |
| CN101032562A (zh) | 一种具有调节血压及保护心脑血管系统作用的保健品及其应用 | |
| DE102009053157A1 (de) | Arzneimittel enthaltend Cholin | |
| D’Elia et al. | Sodium and Potassium | |
| CN107349340A (zh) | 一种预防心血管疾病的ⅲ型寡糖胶囊及其制备方法 | |
| Cullivan et al. | Real-World Experience of Selexipag in Patients with Pulmonary Arterial Hypertension in an Irish Center | |
| Wardle et al. | Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil | |
| Venâncio et al. | Dietary treatment of hyperhomocysteinemia in peripheral arterial disease | |
| Kossmann et al. | Lysozyme M positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction | |
| Olver et al. | Abdominal Obesity Impairs Vasodilation and Insulin Sensitivity in Young Women: 714: Board# 5 8: 00 AM-10: 00 AM |